Skip to main content

Genetic Lung Diseases

Transformative treatments for children with fatal genetic lung diseases


Inherited SP-B deficiency is a genetic disorder affecting approximately 1 in 1 million newborns in the US and Europe. It results from mutations in the SP-B gene, which is essential for lung function and survival.

Current interventions only provide temporary relief, and once genetic diagnosis of SP-B deficiency is confirmed, treatment is usually withdrawn and patients die. The only definitive treatment, lung transplantation, is often not accessible owing to the scarcity of donor organs for newborns and the risks involved. This leaves few if any viable options for long-term survival.

Professor Deborah Gill says: 'It must be devastating to be told that your newborn baby has a fatal disease for which there is no treatment. Surfactant protein B (SPB) deficiency is a rare disease where a baby is born with severe breathing difficulties. The babies cannot keep their lungs inflated and need mechanical ventilation to help keep them alive. Currently, there is no cure or treatment for this disease, but we think gene therapy could help. We aim to deliver a functional copy of the gene responsible for SPB deficiency deep into the babies' lungs to help them make normal lung surfactant so they can breathe independently.'

AlveoGene, co-founded in 2023 by Professor Deborah Gill and Professor Steve Hyde, is developing a gene therapy known as AVG-002 using its InGenuiTy® platform. This uses a unique lentiviral vector to deliver a functional SP-B gene directly to the neonatal deep lung alveolar region with high efficiency and efficacy via respiratory instillation.

AlveoGene has now been awarded a Rare Pediatric Disease Designation (RPDD) by the US Food & Drug Administration (FDA) for AVG-002. This means that it will receive a rare paediatric disease Priority Review Voucher (PRV) when the designated drug is approved for the associated indication in the paediatric population.

The voucher will reduce the product's review time and accelerate any granted approval and subsequent market entry by at least four months. The PRV may be used by the original recipient, or it can be sold to another company for the purchaser's use, with PRVs recently achieving sales prices of $100-$150 million.

Preclinical data in SP-B gene knock-out mouse models demonstrate that a single dose of AVG-002 extends survival substantially longer when compared with reported data of other SP-B deficiency candidates in development. This offers the possibility of a lifelong treatment from a single administration.

These data are further reinforced by findings that confirm the restoration of normal lung histology and function following AVG-002 treatment in disease-induced lung tissues. AlveoGene is therefore advancing its preparations for the clinical development of AVG-002 in lethal neonatal SP-B deficiency with the possibility of filing for marketing authorisation by 2028.

genetic lung diseases, hereditary pulmonary disorders, cystic fibrosis, alpha-1 antitrypsin deficiency, primary ciliary dyskinesia, idiopathic pulmonary fibrosis, pulmonary surfactant metabolism dysfunction, hereditary hemorrhagic telangiectasia, lung cancer genetics, rare lung diseases, congenital lung malformations, pulmonary hypertension genetics, bronchiectasis genetics, connective tissue disease-related ILD, familial pulmonary fibrosis, interstitial lung disease, lung developmental disorders, genetic testing for lung disease, monogenic lung diseases, genomic medicine in pulmonology,

#GeneticLungDiseases, #PulmonaryGenetics, #CysticFibrosis, #Alpha1AntitrypsinDeficiency, #PrimaryCiliaryDyskinesia, #IdiopathicPulmonaryFibrosis, #SurfactantMetabolism, #HereditaryHemorrhagicTelangiectasia, #LungCancerGenetics, #RareLungDiseases, #CongenitalLungMalformations, #PulmonaryHypertension, #BronchiectasisGenetics, #ILD, #FamilialPulmonaryFibrosis, #InterstitialLungDisease, #LungGenetics, #GeneticTesting, #MonogenicLungDiseases, #GenomicMedicine.


International Conference on Genetics and Genomics of Diseases 

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...